Anti-bcma car t-cell therapy ct103a in relapsed or refractory aqp4-igg seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

HIGHLIGHTS

• who: Chuan Qin from the Study design and oversight This is an investigator-initiated, open-label, single-arm, phase , study, which is conducted at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, ChinaThe study was registered at ClinicalTrials.gov, NCT04561557, and the protocol was approved by the Institutional Review Board of Tongji Hospital. All patients provided written informed consents before screening. A detailed treatment plan is provided in the study protocol (Supplementary data). Briefly, leukapheresis was performed to acquire sufficient autologous peripheral-blood mononuclear cells (PBMCs). The CAR-BCMA cells, CT A, was manufactured . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.